<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">JOP</journal-id>
<journal-id journal-id-type="hwp">spjop</journal-id>
<journal-id journal-id-type="nlm-ta">J Psychopharmacol</journal-id>
<journal-title>Journal of Psychopharmacology</journal-title>
<issn pub-type="ppub">0269-8811</issn>
<issn pub-type="epub">1461-7285</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage UK: London, England</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/0269881110393051</article-id>
<article-id pub-id-type="publisher-id">10.1177_0269881110393051</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Short Report</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Alcohol Use Disorders Identification Test (AUDIT) scores are elevated in antipsychotic-induced hyperprolactinaemia</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name><surname>Lawford</surname><given-names>Bruce R</given-names></name>
<xref ref-type="aff" rid="aff1-0269881110393051">1</xref>
<xref ref-type="aff" rid="aff2-0269881110393051">2</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Barnes</surname><given-names>Mark</given-names></name>
<xref ref-type="aff" rid="aff2-0269881110393051">2</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Connor</surname><given-names>Jason P</given-names></name>
<xref ref-type="aff" rid="aff3-0269881110393051">3</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Heslop</surname><given-names>Karen</given-names></name>
<xref ref-type="aff" rid="aff1-0269881110393051">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Nyst</surname><given-names>Phillip</given-names></name>
<xref ref-type="aff" rid="aff2-0269881110393051">2</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Young</surname><given-names>Ross McD</given-names></name>
<xref ref-type="aff" rid="aff1-0269881110393051">1</xref>
</contrib>
</contrib-group>
<aff id="aff1-0269881110393051"><label>1</label>Institute of Health and Biomedical Innovation, Queensland University of Technology, Brisbane, Queensland, Australia</aff>
<aff id="aff2-0269881110393051"><label>2</label>Division of Mental Health, Royal Brisbane and Women’s Hospital, Brisbane, Queensland, Australia</aff>
<aff id="aff3-0269881110393051"><label>3</label>Faculty of Health, The University of Queensland, Brisbane, Queensland, Australia</aff>
<author-notes>
<corresp id="corresp1-0269881110393051">Bruce Lawford, Division of Mental Health, Royal Brisbane and Women’s Hospital, Butterfield Street, Herston, Brisbane, Queensland 4029, Australia Email: <email>bruce_lawford@health.qld.gov.au</email></corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>2</month>
<year>2012</year>
</pub-date>
<volume>26</volume>
<issue>2</issue>
<fpage>324</fpage>
<lpage>329</lpage>
<permissions>
<copyright-statement>© British Association for Psychopharmacology 2012</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="sage">British Association for Psychopharmacology</copyright-holder>
</permissions>
<abstract>
<p>Hyperprolactinaemia in antipsychotic treated patients with schizophrenia is a consequence of D2 receptor (DRD2) blockade. Alcohol use disorder is commonly comorbid with schizophrenia and low availability of striatal DRD2 may predispose individuals to alcohol use. In this pilot study we investigated whether hyperprolactinaemia secondary to pharmacological DRD2 blockade was associated with alcohol use disorder in 219 (178 males and 41 females) patients with schizophrenia. Serum prolactin determinations were made in patients diagnosed with schizophrenia and maintained on antipsychotic agents. Clinical assessment included demographics, family history and administration of the AUDIT (Alcohol Use Disorders Identification Test). Higher AUDIT scores were associated with prolactin-raising antipsychotic medication (<italic>n = </italic>106) compared with prolactin-sparing medication (<italic>n</italic> = 113). Risperidone (<italic>n = </italic>63) treated patients had higher AUDIT scores and prolactin levels than those on other atypical antipsychotics (<italic>n = </italic>113). Across the entire sample, patients with a prolactin greater than 800 mIU/L had higher AUDIT scores and were more likely to exceed the cut-off score for harmful and hazardous alcohol use. These differences were not explained by potential confounds related to clinical features and demographics, comorbidity or medication side-effects. These data suggest that by lowering dosage, or switching to another antipsychotic agent, the risk for alcohol use disorder in those with schizophrenia may be reduced. This hypothesis requires testing using a prospective methodology.</p>
</abstract>
<kwd-group>
<kwd>Alcohol use disorder</kwd>
<kwd>antipsychotic</kwd>
<kwd>DRD2</kwd>
<kwd>hyperprolactinaemia</kwd>
<kwd>schizophrenia</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="section1-0269881110393051" sec-type="intro">
<title>Introduction</title>
<p>Schizophrenia is a devastating, neurodegenerative disorder affecting 1% of the population (<xref ref-type="bibr" rid="bibr2-0269881110393051">Akkaya et al., 2009</xref>). In addition to experiencing disabling positive and negative symptoms, patients with schizophrenia have both a 20% reduction in their life expectancy (<xref ref-type="bibr" rid="bibr35-0269881110393051">Newman and Bland, 1991</xref>) and a higher prevalence of serious morbidity including cardiovascular disease, diabetes and chronic obstructive pulmonary disease (<xref ref-type="bibr" rid="bibr32-0269881110393051">Marder et al., 2004</xref>). Antipsychotic-induced prolactin elevation may also significantly impair health (<xref ref-type="bibr" rid="bibr23-0269881110393051">Henderson and Doraiswamy, 2008</xref>). Risks for prolactin elevation include both type of antipsychotic agent prescribed and individual susceptibility factors. Typical antipsychotics, and the atypical antipsychotics risperidone and amisulpride, can cause marked elevation in serum prolactin levels. For example, patients treated with risperidone have mean prolactin levels twice that of patients treated with typicals and five times higher than those treated with clozapine (<xref ref-type="bibr" rid="bibr50-0269881110393051">Young et al., 2004</xref>). Most other atypical antipsychotics have little or no effect on serum prolactin levels (<xref ref-type="bibr" rid="bibr31-0269881110393051">Lu et al., 2008</xref>). In addition, individual genetic susceptibility, such as the A1 allele of the Taq1A of the D2 dopamine receptor gene, confers additional risk (<xref ref-type="bibr" rid="bibr50-0269881110393051">Young et al., 2004</xref>). Release of prolactin from the pituitary is inhibited by dopamine (<xref ref-type="bibr" rid="bibr38-0269881110393051">Petty, 1999</xref>) and is a consequence of dopamine receptor blockade (<xref ref-type="bibr" rid="bibr25-0269881110393051">Kinon et al., 2003</xref>). Hyperprolactinaemia may lead to sexual dysfunction (decreased libido, impotence and ejaculatory dysfunction), galactorrhoea, menstrual dysfunction (<xref ref-type="bibr" rid="bibr32-0269881110393051">Marder et al., 2004</xref>) and hypogonadism (<xref ref-type="bibr" rid="bibr21-0269881110393051">Haddad and Weick, 2004</xref>). Other reported complications include breast carcinoma (<xref ref-type="bibr" rid="bibr48-0269881110393051">Wang et al., 2002</xref>), autoimmune thyroiditis (<xref ref-type="bibr" rid="bibr39-0269881110393051">Poyraz et al., 2008</xref>), prolactinoma (<xref ref-type="bibr" rid="bibr2-0269881110393051">Akkaya et al., 2009</xref>), and decreased bone mineral density (<xref ref-type="bibr" rid="bibr27-0269881110393051">Kishimoto et al., 2008</xref>).</p>
<p>A lifetime history of DSM-IV alcohol use disorder is present in 33.7% of patients diagnosed with schizophrenia or schizophreniform disorder, making it the most commonly found comorbid condition (<xref ref-type="bibr" rid="bibr41-0269881110393051">Regier et al., 1990</xref>). Mesolimbic and mesocortical DRD2 are involved in alcohol reinforcement and addiction (<xref ref-type="bibr" rid="bibr19-0269881110393051">Goldstein and Volkow, 2002</xref>) via activation of reward circuits. Lack of DRD2 may predispose individuals to alcohol use as a consequence of reward deficiency (<xref ref-type="bibr" rid="bibr9-0269881110393051">Blum et al., 2000</xref>). Reduction in DRD2 numbers results in increased craving behaviour (<xref ref-type="bibr" rid="bibr10-0269881110393051">Blum et al., 2008</xref>). Positron emission tomography (PET) studies suggest that low availability of striatal DRD2 predisposes individuals to alcohol addiction whilst high DRD2 availability is protective against addiction (<xref ref-type="bibr" rid="bibr47-0269881110393051">Volkow et al., 2006</xref>). Furthermore, in detoxified alcohol-dependent men, reduced availability of ventral striatal DRD2 is associated with increased alcohol craving severity. Functional magnetic resonance reveals that low DRD2 availability is also associated with increased cue-induced activation of both the anterior cingulate and medial prefrontal cortices (<xref ref-type="bibr" rid="bibr22-0269881110393051">Heinz et al., 2005</xref>).</p>
<p>DRD2 antagonists increase self-administration of ethanol in rodents selectively bred to prefer alcohol (<xref ref-type="bibr" rid="bibr17-0269881110393051">Dyr et al., 1993</xref>). The importance of DRD2 blockade is supported in humans by the observation that patients treated with clozapine (an antipsychotic with a low DRD2 binding affinity) show reduced alcohol use when compared with those prescribed risperidone (an antipsychotic with a high DRD2 binding affinity) (<xref ref-type="bibr" rid="bibr20-0269881110393051">Green et al., 2003</xref>). Conversely the dopamine agonist bromocriptine reduces alcohol craving for those with alcohol dependence carrying the Taq 1A A1 allele (<xref ref-type="bibr" rid="bibr30-0269881110393051">Lawford et al., 1995</xref>). Given that antipsychotic medication reduces available DRD2 via blockade we hypothesized that antipsychotics would predispose patients to both hyperprolactinaemia and alcohol misuse. Therefore in this pilot study we investigated whether increased antipsychotic DRD2 blockade and consequent decreased availability of DRD2 (as reflected in elevated serum prolactin) was related to alcohol use disorder in patients with schizophrenia.</p>
</sec>
<sec id="section2-0269881110393051" sec-type="materials|methods">
<title>Methods and materials</title>
<sec id="section3-0269881110393051">
<title>Subjects</title>
<p>We recruited patients aged between 18 and 65 years with a DSM IV diagnosis of schizophrenia. A total of 219 unrelated patients were recruited (178 males, 41 females). Their average age was 39.53 years (SD 13.16); 87 participants were inpatients and 132 were outpatients. Exclusion criteria were schizoaffective disorder, bipolar disorder, dementia, organic brain syndrome, major depressive disorder with delusions, epilepsy, illicit substance dependence and pregnancy. Subjects were recruited from the Fortitude Valley Community Mental Health Centre, Royal Brisbane and Women’s Hospital and The Park Centre for Mental Health. Because various psychoactive agents can influence prolactin levels (<xref ref-type="bibr" rid="bibr50-0269881110393051">Young et al., 2004</xref>) patients taking antidepressant, opiate, anxiolytic or mood-stabilising medication were excluded from the study. All patients were treated with antipsychotic monotherapy at a stable dose for a minimum of 4 weeks, however the majority of patients were maintained on a stable dose for a substantially longer period than this. All outpatients were maintained on a stable antipsychotic dose for a period of several months or years. Participants provided informed consent and were able to withdraw from the study at any time without prejudice. Institutional ethics approvals were obtained from the clinics and hospitals involved and the Queensland University of Technology, Australia. The procedures followed were in accordance with the ethical standards of these institutional ethics committees and the Declaration of Helsinki 1975, revised Hong Kong 1989.</p>
</sec>
<sec id="section4-0269881110393051">
<title>Assessments</title>
<p>All of the data collected were cross-sectional. A clinical history was taken by a consultant psychiatrist (SB, BL, MB), a clinical psychologist (RY), or a clinical nurse (RH, KH). Demographic details, including ethnic background, were taken. Two hundred patients identified themselves as Caucasian, nine as Aboriginal, and two of mixed racial origin (data were missing for eight participants). A total of 52 subjects reported a first-degree relative with a history of schizophrenia. All subjects were administered the Alcohol Use Disorders Identification Test (AUDIT) (<xref ref-type="bibr" rid="bibr3-0269881110393051">Babor et al., 2001</xref>). This screening instrument was developed by the World Health Organization as a simple method to identify individuals with alcohol use disorders. A total score greater than or equal to 8 indicates harmful and hazardous alcohol use. A cut-off score of 10 maximises specificity. The AUDIT is a reliable and valid screening instrument for alcohol use disorders in people with schizophrenia (<xref ref-type="bibr" rid="bibr13-0269881110393051">Dawe et al., 2000</xref>).</p>
<p>Many factors are known to increase risk for alcohol use disorder and some of these risk factors may have been present in patients with an elevated serum prolactin. In order to control for factors that have the potential to produce a spurious association, specific data were obtained. Age and gender of participants were recorded. Furthermore, years of illness, antipsychotic dose, medication adherence, total lifetime number of admissions, history of suicide attempts, inpatient/outpatient status, rates of homelessness and employment status, smoking and illicit drug use data were obtained. The General Health Questionnaire (GHQ) (<xref ref-type="bibr" rid="bibr36-0269881110393051">Ormel et al., 1989</xref>) and the Positive and Negative Syndrome Scale (PANSS) (<xref ref-type="bibr" rid="bibr24-0269881110393051">Kay et al., 1987</xref>) were also administered to the participants. The GHQ measures four psychopathological factors: somatic concerns (GHQ1), anxiety/insomnia (GHQ2), social dysfunction (GHQ3) and depression (GHQ4). The GHQ has been widely validated internationally as a means of detecting psychiatric caseness and is sensitive to change (<xref ref-type="bibr" rid="bibr36-0269881110393051">Ormel et al., 1989</xref>). It has also been used to assess symptom severity (<xref ref-type="bibr" rid="bibr29-0269881110393051">Lawford et al., 2003</xref>).</p>
<p>The inter-rater reliability of the PANSS was monitored throughout the data collection period through random and independent administration by two raters. The level of inter-rater agreement was strong for all assessments. Smoking status and information concerning illicit drug use were obtained. Antipsychotic medication dosage was converted to chlorpromazine equivalents and history of medication adherence was noted. Movement disorder was assessed using the Abnormal Involuntary Movements Scale and the Barnes Akathisia Scale (<xref ref-type="bibr" rid="bibr1-0269881110393051">Aberg et al., 2010</xref>).</p>
<p>Serum prolactin determination was conducted at the Royal Brisbane and Women’s Hospital. A heterogeneous sandwich magnetic separation assay (Immuno1system; Bayer Diagnostics, Newbury, Berkshire, UK) standardised against the World Health Organization 3rd IRP 84/500 Reference Manual was employed. Investigators were blind to prolactin determinations when collecting all other data.</p>
</sec>
<sec id="section5-0269881110393051">
<title>Medications</title>
<p>Patients were prescribed either prolactin-raising or prolactin-sparing antipsychotics (<xref ref-type="bibr" rid="bibr49-0269881110393051">Wieck, 2002</xref>). Prolactin-raising medications included risperidone (<italic>n = </italic>63), amisulpride (<italic>n = </italic>2) and typical antipsychotics (<italic>n = </italic>41). These medications commonly induce hyperprolactinaemia. Prolactin-sparing medications, which are less likely to produce hyperprolactinaemia, included olanzapine (<italic>n = </italic>55), clozapine (<italic>n = </italic>49) and quetiapine (<italic>n = </italic>9). Inpatient medication was administered under supervision of nursing staff; outpatient adherence was estimated by self-report and assessment by the treating psychiatrist.</p>
</sec>
<sec id="section6-0269881110393051">
<title>Statistical analysis</title>
<p>Information coded from standardised interview proformas was entered into a computer database along with prolactin determinations. Analysis of variance (ANOVA) was used to compare AUDIT scores among various treatment groups. Chi-square statistic (Fisher’s exact test) was employed to compare differences in a categorical variable (AUDIT score ≥10) between individuals with a prolactin ≥800 mIU/L and those with a prolactin &lt;800 mIU/L. A <italic>p</italic>-value ≤0.05 was considered to be significant. Specific comparisons were made using ANOVA and chi-square analyses to investigate possible confounds. AUDIT items were incomplete for 7 patients, resulting in 212 total AUDIT scores available for analysis.</p>
</sec>
</sec>
<sec id="section7-0269881110393051" sec-type="results">
<title>Results</title>
<p>AUDIT scores among those patients (<italic>n = </italic>104) prescribed prolactin-raising antipsychotics (mean 7.78, SD 8.45) were significantly higher than the scores of those (<italic>n = </italic>107) prescribed prolactin-sparing agents (mean 5.42, SD 6.94), (<italic>F</italic> [1,210] = 4.094, <italic>p = </italic>0.027). ANOVA revealed there was no difference in AUDIT scores between those taking atypical and typical antipsychotic medications (<italic>F</italic> [1,210] = 0.565, <italic>p = </italic>0.453). Effect size calculations indicated that this was a small effect (Cohen’s <italic>d</italic> = 0.31, effect size = 0.027).</p>
<p>Patients administered risperidone had higher AUDIT scores (mean 8.23, SD 8.46) than those administered other atypical agents (mean 5.35, SD 6.9) (<italic>F</italic> [1,171] = 5.82, <italic>p = </italic>0.017). Effect size calculation here indicated a medium effect (Cohen’s <italic>d</italic> = 0.89, effect size = 0.41). In addition the prolactin levels of patients administered risperidone (mean 963.44, SD 724.143) were higher than those found in patients on other atypicals (mean 383.25, SD 431.419) (<italic>F</italic> [1,178] = 45.12, <italic>p</italic> &lt; 0.001). Hyperprolactinaemia is defined using community sample cut-off levels set at a 95% reference range:≥430 mU/L in men and ≥560 mU/L in women (<xref ref-type="bibr" rid="bibr46-0269881110393051">Vanderpump et al., 1998</xref>). ANOVA revealed no significant difference in AUDIT scores in patients who recorded prolactin levels above and below these levels (<italic>F</italic> [1,211] = 2.903, <italic>p</italic> = 0.090). However when patients from the highest quartile of prolactin determinations (≥800 mIU/L, <italic>n = </italic>53) were compared with the rest of the sample, significant differences emerged. AUDIT scores were significantly higher in those patients with a prolactin ≥800 mIU/L (<italic>F</italic> [1,211] = 7.001, <italic>p</italic> = 0.009). The effect size calculation indicated a medium effect (Cohen’s <italic>d</italic> = 0.96, effect size = 0.43). Chi-square analysis established that patients who had a prolactin ≥800 mIU/L were more likely to exceed the AUDIT cut-off score of 10 (<xref ref-type="bibr" rid="bibr3-0269881110393051">Babor et al., 2001</xref>) than patients with a prolactin &lt;800 mIU/L (<italic>n = </italic>159) (χ<sup>2</sup> [1] = 7.3, <italic>p = </italic>0.007).</p>
<p>In order to account for possible confounds, patients who had a prolactin ≥800 mIU/L (<italic>n = </italic>53) were compared with those with a prolactin &lt;800 mIU/L (<italic>n = </italic>159). Potential confounds were grouped into clinical features and demographics, comorbidity and adverse extra pyramidal medication effects. These data, presented as means and proportions, are summarised in <xref ref-type="table" rid="table1-0269881110393051">Table 1</xref>.</p>
<table-wrap id="table1-0269881110393051" position="float">
<label>Table 1.</label>
<caption>
<p>Demographic and clinical features by prolactin level (mIU/L)</p>
</caption>
<graphic alternate-form-of="table1-0269881110393051" xlink:href="10.1177_0269881110393051-table1.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th/>
<th align="left" colspan="2">Prolactin &lt;799 mIU/L</th>
<th align="left" colspan="2">Prolactin ≥800 mIU/L</th>
</tr>
<tr>
<th align="left">Measure</th>
<th align="left">Mean</th>
<th align="left">SD</th>
<th align="left">Mean</th>
<th align="left">SD</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age</td>
<td>40.48</td>
<td>12.38</td>
<td>36.63</td>
<td>15.07</td>
</tr>
<tr>
<td>Years of illness<xref ref-type="table-fn" rid="table-fn1-0269881110393051">**</xref></td>
<td>17.80</td>
<td>12.12</td>
<td>11.98</td>
<td>11.46</td>
</tr>
<tr>
<td>Number of hospital admissions</td>
<td>11.30</td>
<td>14.97</td>
<td>8.31</td>
<td>16.27</td>
</tr>
<tr>
<td>Barnes Akathisia Scale (BAS)</td>
<td>1.63</td>
<td>2.46</td>
<td>2.25</td>
<td>2.67</td>
</tr>
<tr>
<td>Abnormal Involuntary Movements Scale (AIMS)</td>
<td>1.60</td>
<td>3.00</td>
<td>1.19</td>
<td>2.74</td>
</tr>
<tr>
<td>Dose – chlorpromazine equivalent (mg)<xref ref-type="table-fn" rid="table-fn1-0269881110393051">*</xref></td>
<td>507.98</td>
<td>395.08</td>
<td>389.24</td>
<td>319.77</td>
</tr>
<tr>
<td>Positive and Negative Symptom Scale (PANS)</td>
<td>2.94</td>
<td>1.15</td>
<td>2.80</td>
<td>0.97</td>
</tr>
<tr>
<td>Depression (GHQ)</td>
<td>1.22</td>
<td>1.94</td>
<td>1.28</td>
<td>2.15</td>
</tr>
<tr>
<td>Anxiety (GHQ)</td>
<td>1.70</td>
<td>2.10</td>
<td>1.80</td>
<td>2.36</td>
</tr>
<tr>
<td/>
<td>Proportion (%)</td>
<td/>
<td>Proportion (%)</td>
<td/>
</tr>
<tr>
<td>Gender (male proportion)<xref ref-type="table-fn" rid="table-fn1-0269881110393051">*</xref></td>
<td>85.5</td>
<td/>
<td>68.5</td>
<td/>
</tr>
<tr>
<td>Status (inpatient)</td>
<td>41.2</td>
<td/>
<td>34.0</td>
<td/>
</tr>
<tr>
<td>History of medication compliance (yes)</td>
<td>50.9</td>
<td/>
<td>45.3</td>
<td/>
</tr>
<tr>
<td>Current smoker (yes)</td>
<td>79.6</td>
<td/>
<td>79.6</td>
<td/>
</tr>
<tr>
<td>Illicit drug use &lt;12 months (yes)</td>
<td>33.3</td>
<td/>
<td>48.1</td>
<td/>
</tr>
<tr>
<td>Illicit drug use – lifetime (yes)</td>
<td>61.1</td>
<td/>
<td>74.1</td>
<td/>
</tr>
<tr>
<td>History of suicide attempts (yes)</td>
<td>47.7</td>
<td/>
<td>38.0</td>
<td/>
</tr>
<tr>
<td>Homeless (yes)</td>
<td>6.8</td>
<td/>
<td>3.8</td>
<td/>
</tr>
<tr>
<td>Employed (yes)</td>
<td>3.1</td>
<td/>
<td>7.5</td>
<td/>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-0269881110393051">
<label>*</label>
<p><italic>p</italic> &lt; 0.05, **<italic>p</italic> &lt; 0.01.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>Regarding clinical features and demographics ANOVA revealed that patients with a prolactin ≥800 mIU/L had significantly fewer years of illness (<italic>F</italic> [1,203] = 9.317, <italic>p</italic> = 0.003) and were receiving a significantly lower antipsychotic dose as measured in chlorpromazine equivalents (<italic>F</italic> [1,211] = 4.013, <italic>p</italic> = 0.046). ANOVA revealed no significant difference in age between the two groups (<italic>F</italic> [1,211] = 3.530, <italic>p</italic> = 0.062) or lifetime total number of hospital admissions (<italic>F</italic> [1,211] = 1.536, <italic>p</italic> = 0.217). Chi-square analysis, however, revealed a significant difference in gender with females being found more frequently in those with a prolactin ≥800 mIU/L (χ<sup>2</sup> [1] = 7.669, <italic>p = </italic>0.009). There was no difference between the groups with regard to whether they were inpatients or outpatients (χ<sup>2</sup> [1] = 0.883, <italic>p = </italic>0.420) and total positive and negative syndrome scale scores were not different between the groups (<italic>F</italic> [1,210] = 0.720, <italic>p = </italic>0.397). Equally there was no difference in unemployment (χ<sup>2</sup> [1] = 2.010, <italic>p = </italic>0.156) and homelessness (χ<sup>2</sup> [1] = 0.612, <italic>p = </italic>0.434) or medication adherence (χ<sup>2</sup> [1] = 0.509, <italic>p = </italic>0.528).</p>
<p>Regarding comorbidity there were no significant differences in GHQ depression [22] (<italic>F</italic> [1,212] = 0.34, <italic>p = </italic>0.854) and anxiety (<italic>F</italic> [1,212] = 0.83, <italic>p</italic> = 0.774) scores between the two groups. There were no between-group differences in the proportion of current smokers and non-smokers (χ<sup>2</sup> [1] = 0.000, <italic>p = </italic>1.000) or the proportion who used illicit drugs in their lifetime (χ<sup>2</sup> [1] = 2.967, <italic>p = </italic>0.101) or in the 12 months prior to the study (χ<sup>2</sup> [2] = 3.616, <italic>p = </italic>0.068). In addition, there were no differences between the groups with regard to medication adherence (χ<sup>2</sup> [1] = 0.509, <italic>p = </italic>0.528) or history of suicide attempts (χ<sup>2</sup> [1] = 1.435, <italic>p = </italic>0.255).</p>
<p>In terms of extrapyramidal adverse effects there was no difference in Barnes Akathisia Scale total score (<italic>F</italic> [1,215] = 2.417, <italic>p = </italic>0.122) or AIMS total score (<italic>F</italic> [1,215] = 0.814, <italic>p = </italic>0.368).</p>
</sec>
<sec id="section8-0269881110393051" sec-type="discussion">
<title>Discussion</title>
<p>Studies of the prolactin-elevating effects of antipsychotic medication have focussed on sexual dysfunction, infertility, gynaecomastia, galactorrhoea, oligomenorrhoea, amenorrhoea and osteoporosis (<xref ref-type="bibr" rid="bibr21-0269881110393051">Haddad and Weick, 2004</xref>; <xref ref-type="bibr" rid="bibr23-0269881110393051">Henderson and Doraiswamy, 2008</xref>; <xref ref-type="bibr" rid="bibr34-0269881110393051">Montejo, 2008</xref>). The association between alcohol use disorder and antipsychotic-induced prolactin elevation has not been described previously.</p>
<p>We were aware that many factors could act as potential confounds and produce a spurious association. For example rates of alcohol use disorder are higher among males (<xref ref-type="bibr" rid="bibr7-0269881110393051">Batty et al., 2009</xref>). This confound did not influence the association between alcohol use disorder and antipsychotic-induced prolactin elevation as females were over-represented in the group with prolactin ≥800 mIU/L. Potential confounds which could also be associated with alcohol include homelessness and institutional hospital care (<xref ref-type="bibr" rid="bibr41-0269881110393051">Regier et al., 1990</xref>), unemployment (<xref ref-type="bibr" rid="bibr44-0269881110393051">Stankūnas et al., 2009</xref>), social disadvantage (<xref ref-type="bibr" rid="bibr28-0269881110393051">Lamb and Bachrach, 2001</xref>), suicide risk (<xref ref-type="bibr" rid="bibr40-0269881110393051">Preuss et al., 2002</xref>), other substance abuse (<xref ref-type="bibr" rid="bibr11-0269881110393051">Breslau, 1995</xref>; <xref ref-type="bibr" rid="bibr43-0269881110393051">Staines et al., 2001</xref>), psychiatric comorbidity (anxiety disorders and major depression) and age (<xref ref-type="bibr" rid="bibr8-0269881110393051">Bierut et al., 2000</xref>). In addition, alcohol can be used for self-medication for relief of disease symptoms, boredom, dysphoria and poverty and the adverse effects of medication (<xref ref-type="bibr" rid="bibr12-0269881110393051">Chambers et al., 2001</xref>; <xref ref-type="bibr" rid="bibr15-0269881110393051">Dixon et al., 1990</xref>). All of these potential confounds were examined and none of these data supported an association between these risk factors and elevated prolactin (≥800 mIU/L).</p>
<p>Increased alcohol use disorder in patients with a serum prolactin ≥800 mIU/L may occur due to increased blockade of DRD2, resulting in lessened DRD2 availability (<xref ref-type="bibr" rid="bibr47-0269881110393051">Volkow et al., 2006</xref>). This is consistent with functional magnetic resonance imaging revealing that antipsychotic treatment of schizophrenia affects reward system reactivity (<xref ref-type="bibr" rid="bibr26-0269881110393051">Kirsch et al., 2007</xref>).</p>
<p>Alcohol ingestion further raises serum prolactin (<xref ref-type="bibr" rid="bibr14-0269881110393051">De et al., 2002</xref>; <xref ref-type="bibr" rid="bibr18-0269881110393051">Frias et al., 2000</xref>). The exact mechanism for the prolactin-raising effect of alcohol remains unknown but may involve both an increased number of anterior pituitary lactotropes and elevated lactotrope prolactin release (<xref ref-type="bibr" rid="bibr14-0269881110393051">De et al., 2002</xref>). Dopamine and opioid-mediated changes in the hypothalamus may also be contributory (<xref ref-type="bibr" rid="bibr42-0269881110393051">Sarkola et al., 1999</xref>).</p>
<p>Alcohol use disorder in schizophrenia adversely affects the course of the illness. It is associated with significant psychosocial problems including medication non-adherence, poor self-care, financial difficulties and homelessness. In addition, patients with comorbid alcohol abuse and schizophrenia utilise more hospital inpatient services than those without abuse (<xref ref-type="bibr" rid="bibr16-0269881110393051">Drake et al., 1996</xref>). The clinical picture of these comorbid patients is characterised by more severe positive and negative symptoms, hostility, depression, anxiety and suicidal behaviour (<xref ref-type="bibr" rid="bibr5-0269881110393051">Bartels et al., 1992</xref>; <xref ref-type="bibr" rid="bibr6-0269881110393051">Batki et al., 2009</xref>). More than 80% of patients with comorbid schizophrenia and alcohol misuse have at least one chronic medical illness. Medical illness burden is correlated with severity of alcohol use independently of psychosis severity (<xref ref-type="bibr" rid="bibr6-0269881110393051">Batki et al., 2009</xref>). Furthermore, even relatively low consumption of alcohol in patients with schizophrenia profoundly compounds the prominent prefrontal brain volume deficits present independently in both schizophrenia and alcoholism (<xref ref-type="bibr" rid="bibr33-0269881110393051">Mathalon et al., 2003</xref>).</p>
<p>Acamprosate (<xref ref-type="bibr" rid="bibr45-0269881110393051">Tek et al., 2008</xref>), naltrexone and disulfiram (<xref ref-type="bibr" rid="bibr37-0269881110393051">Petrakis et al., 2006</xref>) show preliminary evidence of efficacy in patients with schizophrenia. Furthermore, benefits have been documented from motivational interviewing, cognitive behaviour therapy and family or care-giver intervention in this group of patients (<xref ref-type="bibr" rid="bibr4-0269881110393051">Barrowclough et al., 2001</xref>). Raised serum prolactin in patients with schizophrenia may serve to alert the clinician to the possibility of harmful or hazardous alcohol use and the need for its treatment.</p>
<p>The data presented in this study suggest that antipsychotic-induced hyperprolactinaemia is associated with risk for harmful or hazardous alcohol use in schizophrenia. A preferential prescription of risperidone to the heaviest drinkers in the sample is a potential confound, but this is unlikely. Queensland health policy requires that risperidone is the treatment of choice for all patients on entry to the mental health service. We thus propose that brain reward circuit dysfunction secondary to increased DRD2 blockade is more likely be responsible for this association. Future studies should examine whether this effect is evident in illicit drug users and smokers. The main limitation of this cross-sectional pilot study is that it has multiple confounders and examines an association only. As such causality cannot be assessed and proof of causality would require a prospective randomised controlled trial methodology. If these findings are confirmed, switching to a prolactin-sparing agent or a reduction in dosage may be appropriate strategies in hyperprolactinaemic patients with comorbid alcohol use disorder and schizophrenia. Equally, future studies should examine if avoidance of serum prolactin levels ≥800 mIU/L through application of judicious antipsychotic pharmacotherapy may have the potential to reduce alcohol use disorder in schizophrenia.</p>
</sec>
</body>
<back>
<ack>
<p>The authors would like to acknowledge Simon Burton, Rosa Harrigan and Caroline Taylor for their invaluable assistance in obtaining clinical data.</p>
</ack>
<sec id="section9-0269881110393051">
<title>Funding</title>
<p>This work was partially funded by a competitive Risperidal Research Grant, Janssen-Cilag.</p>
</sec>
<sec id="section10-0269881110393051">
<title>Conflict of interest statement</title>
<p>The authors declare that they have no competing financial interests.</p>
</sec>
<ref-list>
<title>References</title>
<ref id="bibr1-0269881110393051">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Aberg</surname><given-names>K</given-names></name>
<name><surname>Adkins</surname><given-names>DE</given-names></name>
<name><surname>Bukszár</surname><given-names>J</given-names></name>
<name><surname>Webb</surname><given-names>BT</given-names></name>
<name><surname>Caroff</surname><given-names>SN</given-names></name>
<name><surname>Miller del</surname><given-names>D</given-names></name><etal/>
</person-group> (<year>2010</year>) <article-title>Genomewide association study of movement-related adverse antipsychotic effects</article-title>. <source>Biol Psychiatry</source> <volume>67</volume>: <fpage>279</fpage>–<lpage>282</lpage>.</citation>
</ref>
<ref id="bibr2-0269881110393051">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Akkaya</surname><given-names>C</given-names></name>
<name><surname>Kaya</surname><given-names>B</given-names></name>
<name><surname>Kotan</surname><given-names>Z</given-names></name>
<name><surname>Sarandol</surname><given-names>A</given-names></name>
<name><surname>Ersoy</surname><given-names>C</given-names></name>
<name><surname>Kirli</surname><given-names>S</given-names></name>
</person-group> (<year>2009</year>) <article-title>Hyperprolactinaemia and possibly related development of prolactinoma during amisulpride treatment; three cases</article-title>. <source>J Psychopharmacol</source> <volume>23</volume>: <fpage>723</fpage>–<lpage>726</lpage>.</citation>
</ref>
<ref id="bibr3-0269881110393051">
<citation citation-type="book">
<person-group person-group-type="author">
<name><surname>Babor</surname><given-names>TF</given-names></name>
<name><surname>Higgins-Biddle</surname><given-names>JC</given-names></name>
<name><surname>Saunders</surname><given-names>JB</given-names></name>
<name><surname>Monteiro</surname><given-names>MG</given-names></name>
</person-group> (<year>2001</year>) <source>The Alcohol Use Disorders Identification Test. Guidelines for Use in Primary Care</source>, <edition>2nd edn.</edition> <publisher-loc>Geneva</publisher-loc>: <publisher-name>World Health Organization, Department of Mental Health and Substance Dependence</publisher-name>.</citation>
</ref>
<ref id="bibr4-0269881110393051">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Barrowclough</surname><given-names>C</given-names></name>
<name><surname>Haddock</surname><given-names>G</given-names></name>
<name><surname>Tarrier</surname><given-names>N</given-names></name>
<name><surname>Lewis</surname><given-names>SW</given-names></name>
<name><surname>Moring</surname><given-names>J</given-names></name>
<name><surname>O’Brien</surname><given-names>R</given-names></name><etal/>
</person-group> (<year>2001</year>) <article-title>Randomised controlled trial of motivational interviewing, cognitive behaviour therapy and family intervention for patients with co-morbid schizophrenia and substance use disorders</article-title>. <source>Am J Psychiatry</source> <volume>158</volume>: <fpage>1706</fpage>–<lpage>1713</lpage>.</citation>
</ref>
<ref id="bibr5-0269881110393051">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bartels</surname><given-names>SJ</given-names></name>
<name><surname>Drake</surname><given-names>RE</given-names></name>
<name><surname>McHugo</surname><given-names>GJ</given-names></name>
</person-group> (<year>1992</year>) <article-title>Alcohol abuse, depression and suicidal behavior in schizophrenia</article-title>. <source>Am J Psychiatry</source> <volume>149</volume>: <fpage>394</fpage>–<lpage>395</lpage>.</citation>
</ref>
<ref id="bibr6-0269881110393051">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Batki</surname><given-names>SL</given-names></name>
<name><surname>Meszaros</surname><given-names>ZS</given-names></name>
<name><surname>Strutynski</surname><given-names>K</given-names></name>
<name><surname>Dimmock</surname><given-names>JA</given-names></name>
<name><surname>Leontieva</surname><given-names>L</given-names></name>
<name><surname>Ploutz-Snyder</surname><given-names>R</given-names></name><etal/>
</person-group> (<year>2009</year>) <article-title>Medical comorbidity in patients with schizophrenia and alcohol dependence</article-title>. <source>Schizophr Res</source> <volume>107</volume>: <fpage>139</fpage>–<lpage>146</lpage>.</citation>
</ref>
<ref id="bibr7-0269881110393051">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Batty</surname><given-names>GD</given-names></name>
<name><surname>Hunt</surname><given-names>K</given-names></name>
<name><surname>Emslie</surname><given-names>C</given-names></name>
<name><surname>Lewars</surname><given-names>H</given-names></name>
<name><surname>Gale</surname><given-names>CR</given-names></name>
</person-group> (<year>2009</year>) <article-title>Alcohol problems and all-cause mortality in men and women: predictive capacity of a clinical screening tool in a 21-year follow-up of a large, UK-wide, general population-based survey</article-title>. <source>J Psychosom Res</source> <volume>66</volume>: <fpage>317</fpage>–<lpage>321</lpage>.</citation>
</ref>
<ref id="bibr8-0269881110393051">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bierut</surname><given-names>LJ</given-names></name>
<name><surname>Schuckit</surname><given-names>MA</given-names></name>
<name><surname>Hesselbrock</surname><given-names>V</given-names></name>
</person-group> (<year>2000</year>) <article-title>Co-occurring risk factors for alcohol dependence and habitual smoking</article-title>. <source>Alcohol Res Health</source> <volume>24</volume>: <fpage>233</fpage>–<lpage>241</lpage>.</citation>
</ref>
<ref id="bibr9-0269881110393051">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Blum</surname><given-names>K</given-names></name>
<name><surname>Braverman</surname><given-names>ER</given-names></name>
<name><surname>Holder</surname><given-names>JM</given-names></name>
<name><surname>Lubar</surname><given-names>JO</given-names></name>
<name><surname>Chen</surname><given-names>TJ</given-names></name>
<name><surname>Comings</surname><given-names>DE</given-names></name>
</person-group> (<year>2000</year>) <article-title>Reward deficiency syndrome: a biogenetic model for the diagnosis and treatment of impulsive, addictive and compulsive behaviours</article-title>. <source>J Psychoactive Drugs</source> <volume>32</volume>: <fpage>1</fpage>–<lpage>112</lpage>.</citation>
</ref>
<ref id="bibr10-0269881110393051">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Blum</surname><given-names>K</given-names></name>
<name><surname>Chen</surname><given-names>AL</given-names></name>
<name><surname>Chen</surname><given-names>TJ</given-names></name>
<name><surname>Braverman</surname><given-names>ER</given-names></name>
<name><surname>Reinking</surname><given-names>J</given-names></name>
<name><surname>Blum</surname><given-names>SH</given-names></name><etal/>
</person-group> (<year>2008</year>) <article-title>Activation instead of blocking mesolimbic dopaminergic reward circuitry is a preferred modality in the long term treatment of reward deficiency syndrome (RDS): a commentary</article-title>. <source>Theor Biol Med Model</source> <volume>5</volume>: <fpage>24</fpage>.</citation>
</ref>
<ref id="bibr11-0269881110393051">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Breslau</surname><given-names>N</given-names></name>
</person-group> (<year>1995</year>) <article-title>Psychiatric comorbidity of smoking and nicotine dependence</article-title>. <source>Behav Genet</source> <volume>25</volume>: <fpage>95</fpage>–<lpage>101</lpage>.</citation>
</ref>
<ref id="bibr12-0269881110393051">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Chambers</surname><given-names>A</given-names></name>
<name><surname>Krystal</surname><given-names>JH</given-names></name>
<name><surname>Self</surname><given-names>DW</given-names></name>
</person-group> (<year>2001</year>) <article-title>A neurobiological basis for substance abuse comorbidity in schizophrenia</article-title>. <source>Biol Psychiatry</source> <volume>50</volume>: <fpage>71</fpage>–<lpage>83</lpage>.</citation>
</ref>
<ref id="bibr13-0269881110393051">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Dawe</surname><given-names>S</given-names></name>
<name><surname>Seinen</surname><given-names>A</given-names></name>
<name><surname>Kavanagh</surname><given-names>D</given-names></name>
</person-group> (<year>2000</year>) <article-title>An examination of the utility of the AUDIT in people with schizophrenia</article-title>. <source>J Stud Alcohol</source> <volume>61</volume>: <fpage>744</fpage>–<lpage>750</lpage>.</citation>
</ref>
<ref id="bibr14-0269881110393051">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>De</surname><given-names>A</given-names></name>
<name><surname>Boyadjieva</surname><given-names>N</given-names></name>
<name><surname>Oomizu</surname><given-names>S</given-names></name>
<name><surname>Sarkar</surname><given-names>DK</given-names></name>
</person-group> (<year>2002</year>) <article-title>Ethanol induces hyperprolactinemia by increasing prolactin release and lactotrope growth in female rats</article-title>. <source>Alcohol Clin Exp Res</source> <volume>26</volume>: <fpage>1420</fpage>–<lpage>1429</lpage>.</citation>
</ref>
<ref id="bibr15-0269881110393051">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Dixon</surname><given-names>L</given-names></name>
<name><surname>Haas</surname><given-names>G</given-names></name>
<name><surname>Weiden</surname><given-names>P</given-names></name>
<name><surname>Sweeney</surname><given-names>J</given-names></name>
<name><surname>Frances</surname><given-names>A</given-names></name>
</person-group> (<year>1990</year>) <article-title>Acute effects of drug abuse in schizophrenic patients: Clinical observations and patients’ self-reports</article-title>. <source>Schizophr Bull</source> <volume>16</volume>: <fpage>69</fpage>–<lpage>79</lpage>.</citation>
</ref>
<ref id="bibr16-0269881110393051">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Drake</surname><given-names>RE</given-names></name>
<name><surname>Mueser</surname><given-names>KT</given-names></name>
<name><surname>Clark</surname><given-names>RE</given-names></name>
<name><surname>Wallach</surname><given-names>MA</given-names></name>
</person-group> (<year>1996</year>) <article-title>The course, treatment and outcome of substance disorder in persons with severe mental illness</article-title>. <source>Am J Orthopsychiatry</source> <volume>66</volume>: <fpage>42</fpage>–<lpage>51</lpage>.</citation>
</ref>
<ref id="bibr17-0269881110393051">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Dyr</surname><given-names>W</given-names></name>
<name><surname>McBride</surname><given-names>WJ</given-names></name>
<name><surname>Lumeng</surname><given-names>L</given-names></name>
<name><surname>Li</surname><given-names>TK</given-names></name>
<name><surname>Murphy</surname><given-names>JM</given-names></name>
</person-group> (<year>1993</year>) <article-title>Effects of D1 and D2 dopamine receptor agents on ethanol consumption in the high-alcohol-drinking (HAD) line of rats</article-title>. <source>Alcohol</source> <volume>10</volume>: <fpage>207</fpage>–<lpage>212</lpage>.</citation>
</ref>
<ref id="bibr18-0269881110393051">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Frias</surname><given-names>J</given-names></name>
<name><surname>Rodriguez</surname><given-names>R</given-names></name>
<name><surname>Torres</surname><given-names>JM</given-names></name>
<name><surname>Ruiz</surname><given-names>E</given-names></name>
<name><surname>Ortega</surname><given-names>E</given-names></name>
</person-group> (<year>2000</year>) <article-title>Effects of acute alcohol intoxication on pituitary–gonadal axis hormones, pituitary–adrenal axis hormones, beta-endorphin and prolactin in human adolescents of both sexes</article-title>. <source>Life Sci</source> <volume>67</volume>: <fpage>1081</fpage>–<lpage>1086</lpage>.</citation>
</ref>
<ref id="bibr19-0269881110393051">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Goldstein</surname><given-names>RZ</given-names></name>
<name><surname>Volkow</surname><given-names>ND</given-names></name>
</person-group> (<year>2002</year>) <article-title>Drug addiction and its underlying neurobiological basis: Neuroimaging evidence for the involvement of the frontal cortex</article-title>. <source>Am J Psychiatry</source> <volume>159</volume>: <fpage>1642</fpage>–<lpage>1652</lpage>.</citation>
</ref>
<ref id="bibr20-0269881110393051">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Green</surname><given-names>AI</given-names></name>
<name><surname>Burgess</surname><given-names>ES</given-names></name>
<name><surname>Dawson</surname><given-names>R</given-names></name>
<name><surname>Zimmett</surname><given-names>SB</given-names></name>
<name><surname>Strous</surname><given-names>RD</given-names></name>
</person-group> (<year>2003</year>) <article-title>Alcohol and cannabis use in schizophrenia: effects of clozapine vs. risperidone</article-title>. <source>Schizophrenia Res</source> <volume>60</volume>: <fpage>81</fpage>–<lpage>85</lpage>.</citation>
</ref>
<ref id="bibr21-0269881110393051">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Haddad</surname><given-names>PM</given-names></name>
<name><surname>Weick</surname><given-names>A</given-names></name>
</person-group> (<year>2004</year>) <article-title>Antipsychotic-induced hyperprolactinaemia: mechanisms, clinical features and management</article-title>. <source>Drugs</source> <volume>64</volume>: <fpage>2291</fpage>–<lpage>2314</lpage>.</citation>
</ref>
<ref id="bibr22-0269881110393051">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Heinz</surname><given-names>A</given-names></name>
<name><surname>Siessmeier</surname><given-names>T</given-names></name>
<name><surname>Wrasse</surname><given-names>J</given-names></name>
<name><surname>Buchholz</surname><given-names>HG</given-names></name>
<name><surname>Grunder</surname><given-names>G</given-names></name>
<name><surname>Kumakura</surname><given-names>Y</given-names></name><etal/>
</person-group> (<year>2005</year>) <article-title>Correlation of alcohol craving with striatal dopamine synthesis capacity and D2/3 receptor availability: a combined [18F]DMFP PET study in detoxified alcoholic patients</article-title>. <source>Am J Psychiatry</source> <volume>162</volume>: <fpage>1515</fpage>–<lpage>1520</lpage>.</citation>
</ref>
<ref id="bibr23-0269881110393051">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Henderson</surname><given-names>DC</given-names></name>
<name><surname>Doraiswamy</surname><given-names>PM</given-names></name>
</person-group> (<year>2008</year>) <article-title>Prolactin-related and metabolic adverse effects of atypical antipsychotic agents</article-title>. <source>J Clin Psychiatry</source> <volume>69</volume>(<supplement>Suppl 1</supplement>): <fpage>32</fpage>–<lpage>44</lpage>.</citation>
</ref>
<ref id="bibr24-0269881110393051">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kay</surname><given-names>SR</given-names></name>
<name><surname>Fizbein</surname><given-names>A</given-names></name>
<name><surname>Opler</surname><given-names>LA</given-names></name>
</person-group> (<year>1987</year>) <article-title>The positive and negative syndrome scale for schizophrenia</article-title>. <source>Schizophr Bull</source> <volume>13</volume>: <fpage>261</fpage>–<lpage>276</lpage>.</citation>
</ref>
<ref id="bibr25-0269881110393051">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kinon</surname><given-names>BJ</given-names></name>
<name><surname>Gilmore</surname><given-names>JA</given-names></name>
<name><surname>Liu</surname><given-names>H</given-names></name>
<name><surname>Halbreich</surname><given-names>UM</given-names></name>
</person-group> (<year>2003</year>) <article-title>Hyperprolactinemia in response to antipsychotic drugs: characterization across comparative clinical trials</article-title>. <source>Psychoneuroendocrinology</source> <volume>28</volume>(<supplement>Suppl 2</supplement>): <fpage>69</fpage>–<lpage>82</lpage>.</citation>
</ref>
<ref id="bibr26-0269881110393051">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kirsch</surname><given-names>P</given-names></name>
<name><surname>Ronhausen</surname><given-names>S</given-names></name>
<name><surname>Mier</surname><given-names>D</given-names></name>
<name><surname>Gallhofer</surname><given-names>B</given-names></name>
</person-group> (<year>2007</year>) <article-title>The influence of antipsychotic treatment on brain reward system reactivity in schizophrenia patients</article-title>. <source>Pharmacopsychiatry</source> <volume>40</volume>: <fpage>196</fpage>–<lpage>198</lpage>.</citation>
</ref>
<ref id="bibr27-0269881110393051">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kishimoto</surname><given-names>T</given-names></name>
<name><surname>Watanabe</surname><given-names>K</given-names></name>
<name><surname>Shimada</surname><given-names>N</given-names></name>
<name><surname>Makita</surname><given-names>K</given-names></name>
<name><surname>Yagi</surname><given-names>G</given-names></name>
<name><surname>Kashima</surname><given-names>H</given-names></name>
</person-group> (<year>2008</year>) <article-title>Antipsychotic-induced hyperprolactinemia inhibits the hypothalamo–pituitary–gonadal axis and reduces bone mineral density in male patients with schizophrenia</article-title>. <source>J Clin Psychiatry</source> <volume>69</volume>: <fpage>385</fpage>–<lpage>391</lpage>.</citation>
</ref>
<ref id="bibr28-0269881110393051">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lamb</surname><given-names>H</given-names></name>
<name><surname>Bachrach</surname><given-names>L</given-names></name>
</person-group> (<year>2001</year>) <article-title>Some perspectives on deinstitutionalization</article-title>. <source>Psychiatr Serv</source> <volume>52</volume>: <fpage>1039</fpage>–<lpage>1045</lpage>.</citation>
</ref>
<ref id="bibr29-0269881110393051">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lawford</surname><given-names>BR</given-names></name>
<name><surname>Young</surname><given-names>R</given-names></name>
<name><surname>Noble</surname><given-names>EP</given-names></name>
<name><surname>Kann</surname><given-names>B</given-names></name>
<name><surname>Arnold</surname><given-names>L</given-names></name>
<name><surname>Rowell</surname><given-names>J</given-names></name><etal/>
</person-group> (<year>2003</year>) <article-title>D2 dopamine receptor gene polymorphism: paroxetine and social functioning in post-traumatic stress disorder</article-title>. <source>Eur Neuropsychopharmacol</source> <volume>13</volume>: <fpage>313</fpage>–<lpage>320</lpage>.</citation>
</ref>
<ref id="bibr30-0269881110393051">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lawford</surname><given-names>BR</given-names></name>
<name><surname>Young</surname><given-names>RM</given-names></name>
<name><surname>Rowell</surname><given-names>JA</given-names></name>
<name><surname>Qualichefski</surname><given-names>J</given-names></name>
<name><surname>Fletcher</surname><given-names>BH</given-names></name>
<name><surname>Syndulko</surname><given-names>K</given-names></name><etal/>
</person-group> (<year>1995</year>) <article-title>Bromocriptine in the treatment of alcoholics with the D2 dopamine receptor A1 allele</article-title>. <source>Nat Med</source> <volume>1</volume>: <fpage>337</fpage>–<lpage>341</lpage>.</citation>
</ref>
<ref id="bibr31-0269881110393051">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lu</surname><given-names>ML</given-names></name>
<name><surname>Shen</surname><given-names>WW</given-names></name>
<name><surname>Chen</surname><given-names>CH</given-names></name>
</person-group> (<year>2008</year>) <article-title>Time course of the changes in antipsychotic-induced hyperprolactinemia following the switch to aripiprazole</article-title>. <source>Prog Neuropsychopharmacol Biol Psychiatry</source> <volume>32</volume>: <fpage>1978</fpage>–<lpage>1981</lpage>.</citation>
</ref>
<ref id="bibr32-0269881110393051">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Marder</surname><given-names>SR</given-names></name>
<name><surname>Essock</surname><given-names>SM</given-names></name>
<name><surname>Miller</surname><given-names>AL</given-names></name>
<name><surname>Buchanan</surname><given-names>RW</given-names></name>
<name><surname>Casey</surname><given-names>DE</given-names></name>
<name><surname>Davis</surname><given-names>JM</given-names></name><etal/>
</person-group> (<year>2004</year>) <article-title>Physical health monitoring of patients with schizophrenia</article-title>. <source>Am J Psychiatry</source> <volume>161</volume>: <fpage>1334</fpage>–<lpage>1349</lpage>.</citation>
</ref>
<ref id="bibr33-0269881110393051">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Mathalon</surname><given-names>DH</given-names></name>
<name><surname>Pfefferbaum</surname><given-names>H</given-names></name>
<name><surname>Lim</surname><given-names>KO</given-names></name>
<name><surname>Rosenbloom</surname><given-names>MJ</given-names></name>
<name><surname>Sullivan</surname><given-names>EV</given-names></name>
</person-group> (<year>2003</year>) <article-title>Compounded brain volume deficits in schizophrenia–alcoholism comorbidity</article-title>. <source>Arch Gen Psychiatry</source> <volume>60</volume>: <fpage>245</fpage>–<lpage>252</lpage>.</citation>
</ref>
<ref id="bibr34-0269881110393051">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Montejo</surname><given-names>AL</given-names></name>
</person-group> (<year>2008</year>) <article-title>Prolactin awareness: an essential consideration for physical health in schizophrenia</article-title>. <source>Eur Neuropsychopharmacol Suppl</source> <volume>2</volume>: <fpage>S108</fpage>–<lpage>114</lpage>.</citation>
</ref>
<ref id="bibr35-0269881110393051">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Newman</surname><given-names>SC</given-names></name>
<name><surname>Bland</surname><given-names>RC</given-names></name>
</person-group> (<year>1991</year>) <article-title>Mortality in a cohort of patients with schizophrenia: a record linkage study</article-title>. <source>Can J Psychiatry</source> <volume>36</volume>: <fpage>239</fpage>–<lpage>245</lpage>.</citation>
</ref>
<ref id="bibr36-0269881110393051">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ormel</surname><given-names>J</given-names></name>
<name><surname>Koeter</surname><given-names>MW</given-names></name>
<name><surname>Van der Brink</surname><given-names>W</given-names></name>
<name><surname>Giel</surname><given-names>R</given-names></name>
</person-group> (<year>1989</year>) <article-title>Concurrent validity of GHQ-28 and PSE as measures of change</article-title>. <source>Psychol Med</source> <volume>19</volume>: <fpage>1007</fpage>–<lpage>1013</lpage>.</citation>
</ref>
<ref id="bibr37-0269881110393051">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Petrakis</surname><given-names>IL</given-names></name>
<name><surname>Nich</surname><given-names>C</given-names></name>
<name><surname>Ralevski</surname><given-names>E</given-names></name>
</person-group> (<year>2006</year>) <article-title>Psychotic spectrum disorders and alcohol abuse: a review of pharmacotherapeutic strategies and a report on the effectiveness of naltrexone and disulfiram</article-title>. <source>Schizophr Bull</source> <volume>32</volume>: <fpage>616</fpage>–<lpage>617</lpage>.</citation>
</ref>
<ref id="bibr38-0269881110393051">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Petty</surname><given-names>RG</given-names></name>
</person-group> (<year>1999</year>) <article-title>Prolactin and antipsychotic medications: mechanism of action</article-title>. <source>Schizophr Res</source> <volume>35</volume>(<supplement>Suppl</supplement>): <fpage>S67</fpage>–<lpage>S73</lpage>.</citation>
</ref>
<ref id="bibr39-0269881110393051">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Poyraz</surname><given-names>BC</given-names></name>
<name><surname>Aksoy</surname><given-names>C</given-names></name>
<name><surname>Balcioglu</surname><given-names>I</given-names></name>
</person-group> (<year>2008</year>) <article-title>Increased incidence of autoimmune thyroiditis in patients with antipsychotic-induced hyperprolactinaemia</article-title>. <source>Eur Neuropsychopharmacol</source> <volume>18</volume>: <fpage>667</fpage>–<lpage>672</lpage>.</citation>
</ref>
<ref id="bibr40-0269881110393051">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Preuss</surname><given-names>U</given-names></name>
<name><surname>Schuckit</surname><given-names>MA</given-names></name>
<name><surname>Smith</surname><given-names>TL</given-names></name>
<name><surname>Danko</surname><given-names>GP</given-names></name>
<name><surname>Buckman</surname><given-names>K</given-names></name>
<name><surname>Bierut</surname><given-names>L</given-names></name><etal/>
</person-group> (<year>2002</year>) <article-title>Comparison of 3190 alcohol-dependent individuals with and without suicide attempts</article-title>. <source>Alcohol Clin Exp Res</source> <volume>26</volume>: <fpage>471</fpage>–<lpage>477</lpage>.</citation>
</ref>
<ref id="bibr41-0269881110393051">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Regier</surname><given-names>DA</given-names></name>
<name><surname>Farmer</surname><given-names>ME</given-names></name>
<name><surname>Rae</surname><given-names>DS</given-names></name>
<name><surname>Locke</surname><given-names>BZ</given-names></name>
<name><surname>Keith</surname><given-names>SJ</given-names></name>
<name><surname>Judd</surname><given-names>LL</given-names></name><etal/>
</person-group> (<year>1990</year>) <article-title>Comorbidity of mental disorders with alcohol and other drug abuse: Results from the Epidemiological Catchment Area (ECA) study</article-title>. <source>JAMA</source> <volume>264</volume>: <fpage>2511</fpage>–<lpage>2518</lpage>.</citation>
</ref>
<ref id="bibr42-0269881110393051">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Sarkola</surname><given-names>T</given-names></name>
<name><surname>Makisalo</surname><given-names>H</given-names></name>
<name><surname>Fukunaga</surname><given-names>T</given-names></name>
<name><surname>Eriksso</surname><given-names>CJP</given-names></name>
</person-group> (<year>1999</year>) <article-title>Acute effect of alcohol on estradiol, estrone, progesterone, prolactin, cortisol and luteinizing hormone in premenopausal women</article-title>. <source>Alcohol Clin Exp Res</source> <volume>23</volume>: <fpage>976</fpage>–<lpage>982</lpage>.</citation>
</ref>
<ref id="bibr43-0269881110393051">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Staines</surname><given-names>GL</given-names></name>
<name><surname>Magura</surname><given-names>S</given-names></name>
<name><surname>Foote</surname><given-names>J</given-names></name>
<name><surname>Deluca</surname><given-names>A</given-names></name>
<name><surname>Kosanke</surname><given-names>N</given-names></name>
</person-group> (<year>2001</year>) <article-title>Polysubstance use among alcoholics</article-title>. <source>J Addict Dis</source> <volume>20</volume>: <fpage>53</fpage>–<lpage>69</lpage>.</citation>
</ref>
<ref id="bibr44-0269881110393051">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Stankūnas</surname><given-names>M</given-names></name>
<name><surname>Kalediene</surname><given-names>R</given-names></name>
<name><surname>Starkuviene</surname><given-names>S</given-names></name>
</person-group> (<year>2009</year>) <article-title>Sense of coherence and its associations with psychosocial health: results of survey of the unemployed in Kaunas</article-title>. <source>Medicina (Kaunas)</source> <volume>45</volume>: <fpage>807</fpage>–<lpage>813</lpage>.</citation>
</ref>
<ref id="bibr45-0269881110393051">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Tek</surname><given-names>C</given-names></name>
<name><surname>Srihari</surname><given-names>V</given-names></name>
<name><surname>Tek</surname><given-names>E</given-names></name>
</person-group> (<year>2008</year>) <article-title>Successful acamprosate treatment of alcohol dependence in schizophrenia</article-title>. <source>Schizophr Res</source> <volume>106</volume>: <fpage>373</fpage>.</citation>
</ref>
<ref id="bibr46-0269881110393051">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Vanderpump</surname><given-names>MP</given-names></name>
<name><surname>French</surname><given-names>JM</given-names></name>
<name><surname>Appleton</surname><given-names>D</given-names></name>
<name><surname>Tunbridge</surname><given-names>WM</given-names></name>
<name><surname>Kendall-Taylor</surname><given-names>P</given-names></name>
</person-group> (<year>1998</year>) <article-title>The prevalence of hyperprolactinaemia and association with markers of autoimmune thyroid disease in survivors of the Whickam Survey cohort</article-title>. <source>Clin Endocrinol</source> <volume>48</volume>: <fpage>39</fpage>–<lpage>44</lpage>.</citation>
</ref>
<ref id="bibr47-0269881110393051">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Volkow</surname><given-names>ND</given-names></name>
<name><surname>Wang</surname><given-names>GJ</given-names></name>
<name><surname>Begleiter</surname><given-names>H</given-names></name>
<name><surname>Porjesz</surname><given-names>B</given-names></name>
<name><surname>Fowler</surname><given-names>JS</given-names></name>
<name><surname>Telang</surname><given-names>F</given-names></name><etal/>
</person-group> (<year>2006</year>) <article-title>High levels of dopamine D(2) receptors in unaffected members of alcoholic families: possible protective factors</article-title>. <source>Arch Gen Psychiatry</source> <volume>63</volume>: <fpage>999</fpage>–<lpage>1008</lpage>.</citation>
</ref>
<ref id="bibr48-0269881110393051">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Wang</surname><given-names>PS</given-names></name>
<name><surname>Walker</surname><given-names>AM</given-names></name>
<name><surname>Tsuang</surname><given-names>MT</given-names></name>
<name><surname>Orav</surname><given-names>EJ</given-names></name>
<name><surname>Glynn</surname><given-names>RJ</given-names></name>
<name><surname>Levin</surname><given-names>R</given-names></name><etal/>
</person-group> (<year>2002</year>) <article-title>Dopamine antagonism and the development of breast cancer</article-title>. <source>Arch Gen Psychiatry</source> <volume>59</volume>: <fpage>1147</fpage>–<lpage>1154</lpage>.</citation>
</ref>
<ref id="bibr49-0269881110393051">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Wieck</surname><given-names>A</given-names></name>
</person-group> (<year>2002</year>) <article-title>Hyperprolactinaemia caused by antipsychotic drugs. This common side effect needs more attention</article-title>. <source>BMJ</source> <volume>324</volume>: <fpage>250</fpage>–<lpage>252</lpage>.</citation>
</ref>
<ref id="bibr50-0269881110393051">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Young</surname><given-names>RMcD</given-names></name>
<name><surname>Lawford</surname><given-names>BR</given-names></name>
<name><surname>Barnes</surname><given-names>M</given-names></name>
<name><surname>Burton</surname><given-names>SC</given-names></name>
<name><surname>Ritchie</surname><given-names>T</given-names></name>
<name><surname>Ward</surname><given-names>WK</given-names></name><etal/>
</person-group> (<year>2004</year>) <article-title>Prolactin levels in antipsychotic treatment of patients with schizophrenia carrying the DRD2* A1 allele</article-title>. <source>Br J Psychiatry</source> <volume>185</volume>: <fpage>147</fpage>–<lpage>151</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>